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Abstract
Single-stranded polyanions $40 bases in length facilitate the formation of hamster scrapie prions in vitro, and polyanions
co-localize with PrP
Sc aggregates in vivo [1,2]. To test the hypothesis that intact polyanionic molecules might serve as a
structural backbone essential for maintaining the infectious conformation(s) of PrP
Sc, we produced synthetic prions using a
photocleavable, 100-base oligonucleotide (PC-oligo). In serial Protein Misfolding Cyclic Amplification (sPMCA) reactions
using purified PrP
C substrate, PC-oligo was incorporated into physical complexes with PrP
Sc molecules that were resistant to
benzonase digestion. Exposure of these nuclease-resistant prion complexes to long wave ultraviolet light (315 nm) induced
degradation of PC-oligo into 5 base fragments. Light-induced photolysis of incorporated PC-oligo did not alter the
infectivity of in vitro-generated prions, as determined by bioassay in hamsters and brain homogenate sPMCA assays.
Neuropathological analysis also revealed no significant differences in the neurotropism of prions containing intact versus
degraded PC-oligo. These results show that polyanions .5 bases in length are not required for maintaining the infectious
properties of in vitro-generated scrapie prions, and indicate that such properties are maintained either by short polyanion
remnants, other co-purified cofactors, or by PrP
Sc molecules alone.
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Introduction
Infectious prion diseases such as Creutzfeldt Jakob disease (CJD)
and other related human disorders, chronic wasting disease (CWD),
bovine spongiform encephalopathy (BSE), and scrapie are associ-
ated with the conversion of a host-encoded glycoprotein (PrP
C)i n t o
a misfolded conformer, PrP
Sc [3]. Several biochemical studies
utilizing the protein misfolding cyclic amplification (PMCA)
technique have shown that PrP
Sc is an essential component of the
infectious agent [4,5,6].
Interestingly, a variety of prion strains with distinctive infectious
phenotypes, such as selective neurotropism and characteristic
disease incubation times, have been isolated and propagated in vivo
and in vitro [7,8]. In some cases, infection with specific prion strains
produces PrP
Sc molecules with distinctive biochemical character-
istics, suggesting that multiple self-propagating PrP
Sc conforma-
tions may provide the structural basis for the existence of multiple
prion strains [9,10].
Several biochemical and cell culture studies have implicated
polyanions such as single stranded nucleic acid and glycosamino-
glycan (GAG) molecules as potent cofactors in the process of
infectious prion propagation [1,5,6,11,12,13,14,15,16,17]. More-
over, it has been shown that polyanions are selectively incorpo-
rated into physical complexes with purified PrP molecules in
infectious hamster prions, and that a minimum length corre-
sponding to a 40 base single stranded oligonucleotide is required
for a polyanion to facilitate hamster prion formation in vitro [1].
Neuropathological analysis of scrapie-infected animals has shown
that nucleic acids and GAG-containing proteoglycans co-localize
with PrP
Sc aggregates in situ [1,2]. Collectively, these observations
raise the possibility that moderately long polyanions might be
needed to maintain hamster prion infectivity or strain properties
by acting as a structural support for PrP
Sc molecules.
Nuclease-resistant RNA molecules have been detected in
purified prion preparations [18], and analytical methods suggest
that the average size of polynucleotides in such preparations is
#25 nucleotides, assuming a ratio of 1 polynucleotide molecule
per infectious unit [19]. More recently, Jeong et al. reported
reduction of prion infectivity and PrP
Sc by treatment of hamster
263K scrapie brain homogenates with LiAlH4 (lithium aluminum
hydride), a highly reactive reducing agent capable of degrading
RNA molecules [20]. However, because LiAlH4 is a non-specific
reducing agent, which can react with a variety of biological
molecules other than RNA, including proteins, it is not possible to
ascribe definitively the detrimental effect of LiAlH4 on prion
infectivity to the degradation of RNA.
Previous photo-irradiation studies of naturally occurring prions
[21,22] suggested that specific nucleic acid sequences are not
necessary for prion infectivity, and this conclusion was confirmed
by the de novo formation of purified prions using synthetic,
homopolymeric poly(A) RNA molecules [5]. However, these prior
studies did not exclude a structural, non-coding role for polyanions
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since ultraviolet (UV) light mutates pyrimidine bases but does not
significantly degrade the polynucleotide backbone of nucleic acids
or other types of polyanions such as GAGs.
Here we report the results of studies using purified synthetic
prions containing a photocleavable (dT)100 oligonucleotide (PC-
oligo), which can be selectively degraded in situ into 5-mers by
exposure to long wave UV light. This approach directly addresses
the question of whether polyanions might serve as a structural
backbone for infectious prions in a chemically defined model
system.
Materials and Methods
Reagents
Hamster prion strain Sc237 was kindly provided by Dr. Stanley
Prusiner (UCSF, San Francisco, CA). Three-week-old female
Golden Syrian hamsters used in inoculation experiments and
seven-week-old Golden Syrian hamsters used to make brain
homogenates were purchased from Charles River (Wilmington,
MA). Monoclonal antibody (mAb) 6D11 was purchased from
Covance (Princeton, NJ). PC-oligo was chemically synthesized by
placing a photocleavable group in between every five base of
(dT)100, using (3-(4,49-Dimethoxytrityl)-1-(2-nitrophenyl)-propan-
1-yl-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite). PC-oligo
was synthesized by and purchased from Gene Link (Hawthorne,
NY). Stock solutions of PC-oligo were made by dissolving
lyophilized powder into 50% DMSO/ 50% TE pH 8.0 (10 mM
Tris 8.0, 1 mM EDTA) to a final concentration of 5 mg/ml. The
dT-oligo was synthesized by and purchased from Operon
(Huntsville, AL). Wild type mouse recombinant PrP was expressed
in E. Coli and purified as previously described [6]. Benzonase
nuclease (50-230-8706) was purchased from EMD Chemicals
(Gibbstown, NH).
Serial Protein Misfolding Cyclic Amplification (sPMCA)
sPMCA reactions were performed as previously described [4,5].
Reaction tubes were subjected to PMCA for 24 h using a Misonix
s3000 programmable sonicator equipped with a microplate horn
(Misonix, Farmingdale, NY) containing 350 ml of water. The
temperature was maintained inside the horn by a circulating water
bath, pumping warmed water through aluminum coils surround-
ing the horn. Sample tubes were held in a plastic rack which
prevents lid opening and hold tubes ,3 mm from the surface of
the horn. After 24 h, the tubes were removed from the sonicator,
and 10 ml of the reaction mixture was added to a new tube
containing fresh substrate.
Western Blotting
A portion of each sample was treated with 25 mg/ml proteinase
K for 30 min at 37uC shaking at 750 rpm in an Eppendorf
Thermomixer (Fisher Scientific, Pittsburg, PA). An equal volume
of 2x sodium dodecyl sulfate (SDS) loading buffer was added to
each tube and then boiled at 95uC for 10 min. SDS-polyacryl-
amide gel electrophoresis (PAGE) was then performed using
1.5 mm 12% polyacrylamide gels (29:1 acrylamide:bisacrylamide)
The gel was transferred to a methanol-charged polyvinylidene
difluoride membrane (Millipore, Billerica, MA) using a Transblot
SD semidry transfer cell (Bio-Rad, Hercules, CA). The transfer
was set to achieve 3 mA/cm
2 for 30 min. After transfer, the
membrane was incubated in 20% (v/v) instant nonfat dry milk
(Nestle, Vevey, Switzerland) dissolved in TBST (10 mM Tris
pH 7.1, 150 mM NaCl, 0.1% Tween 20). The membrane was
then incubated overnight at 4uC with mAb 6D11 in TBST (final
concentration 80 ng/ml). The membrane was washed 3 times with
TBST for 10 min and then incubated for 1 h with horseradish
peroxidase-labeled anti-mouse immunoglobulin G secondary
antibody conjugate (GE Healthcare) diluted 1:5,000 in TBST.
Again the membrane was washed 4 times for 10 min in TBST.
Blots were developed with West Pico (Pierce, Rockford, IL)
chemiluminescence substrate. Images were captured using a Fuji
LAS-3000 chemiluminescence documentation system (Fujifilm,
Tokyo, Japan). Relative molecular masses were determined by
comparison to prestained standards from Fermentas (Hanover,
MD).
Preparation of Purified PrP
Sc Molecules
Immunopurified PrP
C was prepared as described previously [5].
To produce substrate mixtures, 37.5 ml of immunopurified PrP
C
was mixed with 10 ml of 10x reaction buffer (200 mM MOPS
pH 7.5, 10% Triton X-100, 500 mM imidazole, 50 mM EDTA,
1.5 M NaCl), 7.5 ml of dT-oligo or PC-oligo (0.3 mg/ml for a total
of 2.25 mg) and 35 ml of molecular grade water (Mediatech,
Herndon, VA). On the first day, 10 ml of Sc237 brain homogenate
was added to a 0.5 ml thin-walled PCR tube (Axygen, Union City,
CA) and subjected to sPMCA as described above. The sonicator
delivered bursts of 30 s every 30 min at output 6.5. sPMCA was
continued for 15 days, effectively diluting the original inocula 10
15
fold. The negative control line was treated as stated above with the
omission of nucleic acid from the substrate cocktail.
Light Treatment of Oligonucleotides
dT-oligo and PC-oligo were placed in their own ProxiPlate 96-
well plate (PerkinElmer, Waltham, MA). The plates were placed
into a UV Stratalinker 2400 (Stratagene, La Jolla, CA) equipped
with bulbs that emit light at 315 nm. The 96-well plates were
placed on top of tip boxes and racks so samples were ,2.5 cm
from the light source. Each light treated sample received 4 pulses
of light at an energy level of 500,000 mJ. Non-light treated samples
were also placed in their own ProxiPlate 96-well plate but were
then placed inside a drawer to protect from light. Treated and
non-treated oligos were either added to sPMCA reactions as
described above, or directly analyzed as described below. For
benzonase protection assays 6 mg of either dT-oligo or PC-oligo
were incubated for 10 min at 37uC and shaking at 750 rpm with
or without 300 mg recPrP. After incubation samples were
sonicated for one 30 s pulse followed by another 10 min
incubation at 37uC and 750 rpm. After second incubation 7 ml
of benzonase was added (175 units) and further Incubated for 1 h
Author Summary
Prions are unorthodox infectious agents whose composi-
tion remains undetermined. Previous experiments have
shown that long, negatively charged polymers such as
nucleic acid and carbohydrate molecules promote the
formation of purified prions in test tube chemical
reactions. Various classes of negatively charged polymers
have also been found to co-exist within prion complexes in
the brains of infected animals. These observations suggest
that negatively charged polymers might act as a structural
support necessary for prion infectivity. We tested this
possibility by chemically synthesizing a negatively charged
polymer that can be degraded by exposure to ultraviolet
light. Prions containing this light-sensitive polymer re-
mained infectious after light exposure, indicating that
negatively charged polymers are not necessary to maintain
the structural shapes of infectious prions.
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described below.
Light Treatment of PrP
Sc Samples
Concentrations of PrP
Sc containing either dT-oligo or PC-oligo
were compared by Western blot and diluted to achieve equal
concentrations. Of the normalized material, 500 ml of each sample
was placed in its own ProxiPlate 96-well plate (PerkinElmer,
Waltham, MA). Samples were then treated as described above
with one modification. In between each light pulse, samples were
removed from the 96-well plate, placed in a 1.5 ml tube and
subjected to sonication in a cold sonicator. Briefly, 350 ml of
chilled water was placed in the microplate horn, and tubes were
positioned in a rack as described above and subjected to a 20 s
pulse at output 6.5. Samples were returned to new wells in the 96-
well plate and subjected to another round of light or dark
treatment.
DNA Recovery and Analysis
To analyze the effect of light on the nucleic acids 150 ml of each
sample was brought to 250 ml by adding 1x reaction buffer. An
equal volume of Phenol:Chloroform:Isoamyl alcohol 25:24:1
(Sigma, St. Louis, MO) was added to each tube and vortexed.
Samples were spun at 14,0006 g for 2 min. The top aqueous
phase was carefully removed and the process repeated twice more.
After three extractions with the Phenol:Chloroform:Isoamyl
alcohol, an equal volume of chloroform was added to each tube,
vortexed and spun as above. The top aqueous phase was removed
and to it 25 ml of 3 M sodium acetate pH 7.0 was added followed
by 750 ml of 95% EtOH. Tubes were vortexed and incubated at
220uC for 15 min. After incubation tubes were spun at 14,0006g
for 10 min to pellet the DNA. The pellet was washed with 80%
EtOH, spun and dried. The pellet was resuspended in equal
volumes of TE (10 mM Tris pH 7.0, 1 mM EDTA) and 2x TBE-
Urea sample buffers (Invitrogen, Carlsbad, CA). Samples were
boiled at 95uC for 5 min and then loaded into pre-cast 15% TBE-
Urea acrylamide gels (Invitrogen, Carlsbad, CA). Gels were run in
a X-Cell SureLock apparatus (Invitrogen, Carlsbad, CA) at 200 V
for 50 min. Molecular weight ladder was made by mixing oligo dT
100mer, oligo dT 30mer and oligo dT 10mer (10 mg/ml) in a
ratio of 1:3:9 with 2x TBE-Urea sample buffer (oligos purchased
from Operon, Huntsville, AL). Gels were then stained for 1 h with
Sybr Gold (Invitrogen, Carlsbad, CA) diluted 1:10,000 in TBE
(89 mM Tris-base, 89 mM Boric Acid, 2 mM EDTA pH 8.3).
After staining, gels were visualized on a transilluminator and
photographed with a Canon Power Shot A650 IS (Canon, Tokyo,
Japan) equipped with proper filters.
sPMCA End Point Titration
A 10% hamster brain homogenate (w/v) was made in
conversion buffer (PBS with 150 mM NaCl, 1% Triton X-100,
4 mM EDTA) plus a Complete PI tablet with EDTA (Poche,
Indianapolis, IN) using a polytron tissue grinder. The homogenate
was then spun at 2006 g for 30 s. The supernatant was then
aliquotted into 0.5 ml thin-walled PCR tubes (90 ml reactions) and
frozen at 270uC until used. PrP
Sc molecules treated with or
without light were serially diluted into conversion buffer (PBS with
150 mM NaCl, 1% Triton X-100, 5 mM EDTA) to create 10
titers ranging from 10
21–10
210. Each titer was used to start a
reaction by adding 10 mlt o9 0ml of brain homogenate prepared as
described above. Samples were subjected to 3 rounds of sPMCA as
described above. The sonicator for this experiment was set to
deliver 30 s pulses at output 8.5. Each sample was Western blotted
as described above.
Preparation of Inocula
For each of the lines injected, 20 ml of day 15 material was
spiked into each of 5 reaction tubes containing 200 ml of fresh
substrate cocktail and subjected to 1 cycle of PMCA as described
above. After 24 h tubes were removed and combined. This
material was then treated with or without light as described above.
After treatments, 100 ml of each sample was diluted into 900 mlo f
sterile PBS with 5 mg/ml bovine serum albumin (BSA) to prepare
the inoculum. The DNA alone inoculum was prepared by mixing
2.25 mg of each nucleic acid into 100 ml of 1x reaction buffer. This
material was then diluted 1:10 into 5 mg/ml BSA, as described
above.
Scrapie Inoculation and Diagnosis
Injections were performed in laminar-flow biosafety cabinets
using disposable syringes, gloves and surfaces. Intracerebral
inoculations were performed using 28-gauge hypodermic needles
inserted into the parietal lobe. Each animal received 50 mlo f
inoculum. Hamsters were examined daily by veterinary staff
blinded to experimental groups. Standard diagnostic criteria were
used to identify animals showing signs of scrapie.
Neuropathology
Animals were euthanized by CO2 inhalation until death was
imminent. Their brains were quickly removed using sterile
dissection instruments on disposable surfaces. Brains were
immersed in 10% buffered formalin for 1 week. Sagittal and
parasagittal sections were made and brains placed into tissue-
processing cassettes. The cassettes were immersed into 90% formic
acid for 1 hr and then placed into 10% formalin. Tissues were
next embedded in paraffin and cut into 4 mm sections. Sections
were stained with hematoxylin and eosin. A single neuropathol-
ogist, who was blinded to the experimental groups examined all
slides and scored them according to the degree of vacuolation.
Scores were made according to previously published standards [5].
Ethics Statement
All animals were handled in strict accordance with good animal
practice, as defined by the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
Dartmouth College Institutional Animal Care and Use Committee
approved the animal work (assurance number A3259-01).
Inoculations were performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Results
We chemically synthesized a 100-base poly-dT molecule
containing with a UV-photocleavable group (PC-oligo) every five
bases (Figure 1). To confirm that PC-oligo can support PrP
Sc
propagation, sPMCA reactions containing purified Syrian hamster
PrP
C supplemented with either PC-oligo or dT-oligo were seeded
with Sc237 brain homogenate. The PrP
C substrate used in these
studies has been previously characterized extensively by a variety
of analytical methods, and was found to contain stoichiometric
quantities of co-purified endogenous lipids; but no other proteins,
nucleic acids, or specific metal ions [5]. The results of our
preliminary experiment show that both PC-oligo and dT-oligo
support PrP
Sc propagation through three rounds of sPMCA
reactions whereas control reactions without added polyanions
failed to propagate (Figure S1 in Supporting Information S1).
After proteinase K (PK) digestion, PrP
Sc molecules formed with
either oligonucleotide showed a similar shift in electrophoretic
mobility to 27–30 kD (Figure S1 in Supporting Information S1).
Prion Polyanion Degradation
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photolysis of PC-oligo, pure solutions of each oligonucleotide in
buffer were treated with varying amounts of UV light (315 nm)
and analyzed by acrylamide gel electrophoresis. Prior to light
treatment, PC-oligo can be seen a 5-base ladder, representing the
collection of full length and incomplete products formed during
the sequential conjugation chemical synthesis protocol (Figure S2
in Supporting Information S1, lane 3). Upon exposure to two
Joules of light, PC-oligo was completely degraded to 5-base
oligonucleotide units (Figure S2 in Supporting Information S1,
compare lanes 3 and 7) while dT-oligo remained intact (Figure S2
in Supporting Information S1, compare lanes 1 and 2).
We next tested the effect of light-induced degradation on the
ability of PC-oligo to facilitate prion propagation in sPMCA
reactions. As anticipated, dT-oligo supported propagation of
Sc237 prions in sPMCA reactions using immunopurified hamster
PrP
C substrate even when the control oligonucleotide was
pretreated with UV light (Figure 2, left gels). PC-oligo pretreated
with UV light did not support propagation (Figure 2, bottom right
gel), whereas PC-oligo mock-treated in the dark supported Sc237
propagation in sPMCA for three rounds (Figure 2, top right gel).
These results confirm our previously published results that an
oligonucleotide must be at least 40 bases long to support
propagation, and that our light treatment protocol completely
degrades PC-oligo to a length smaller than that required for
efficient propagation in sPMCA.
We previously found that single stranded nucleic acids form a
nuclease-resistant complex with both PrP
C and PrP
Sc molecules
during sPMCA reactions[1]. To study the penetration of UV light
into nucleoprotein complexes, we combined a stoichiometric
excess of full-length recombinant mouse PrP (recPrP) with our test
oligonucleotides. Following PMCA sonication, both PC-oligo and
dT-oligo became completely protected from nuclease digestion,
whereas both oligonucleotides were nuclease-sensitive in the
absence of PrP (Figures 3A and 3B). UV irradiation induced the
degradation of PC-oligo, but not dT-oligo, within these nuclease-
resistant complexes containing excess PrP (compare Figure 3A,
lanes 7–8 and Figure 3B, lanes 7–8). Thus, UV light is able to
penetrate PrP nucleoprotein complexes, providing us with a
unique opportunity to control the degradation of PC-oligo in situ
within purified prions.
Having established conditions for UV light penetration of PrP
nucleoprotein complexes, we sought to determine the effect of
light-induced degradation of PC-oligo in situ (i.e. already
incorporated into complexes PrP
Sc molecules) on the conforma-
tional stability, sPMCA seeding activity, and biological infectivity
of synthetic PrPSc molecules. PrP
Sc molecules containing either
PC-oligo or control dT-oligo were generated by performing
sPMCA for 15 rounds in order to dilute the initial prion seeds
several orders of magnitude beyond the calculated endpoint [4,5],
and then either treated with UV light or mock-treated in the dark.
A PK digestion assay revealed no significant differences in PrP
Sc
Figure 1. Schematic showing the composition of the PC-oligo.
Repeating units of five deoxythymine residues were followed by a
photocleavable (PC) linker as shown. Enlarged inset shows the chemical
structure of the PC linker (3-(4,49-Dimethoxytrityl)-1-(2-nitrophenyl)-
propan-1-yl-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite). The
arrow indicates the location of the cleavage site (the phosphodiester
bond between the linker and the 59 phosphate of the oligonucleotide).
doi:10.1371/journal.ppat.1002001.g001
Figure 2. Western blot showing the effect of degrading PC-
oligo on its ability to stimulate prion conversion in sPMCA.
Lanes 1 and 6 show non-digested PrP
C used as substrate (-PK). The
remaining samples were subjected to limited proteolysis with
proteinase K.
doi:10.1371/journal.ppat.1002001.g002
Figure 3. Acrylamide gel electrophoresis showing the effects of
benzonase and light treatment on oligonucleotide integrity. A.
Experiments performed with dT-oligo. B. Experiments performed with
PC-oligo. In both panels, treatments were performed on oligonucleo-
tides in the presence or absence of 1.5 mg/ml recPrP, as indicated.
doi:10.1371/journal.ppat.1002001.g003
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samples (Figure S3 in Supporting Information S1). To measure
sPMCA seeding activity, samples were serially titrated, and the
resulting dilutions were used to seed three rounds of sPMCA using
fresh hamster brain homogenate as substrate, and samples from
the final round of sPMCA were analyzed for the presence of PrP
Sc
by Western blot. The results of this quantitative end-point titration
assay show that PrP
Sc molecules containing either dT-oligo or PC-
oligo were equally susceptible to UV irradiation; both sets of
samples displayed ,1 log decrease in seed titer upon light
treatment, presumably due to non-specific effects (Figure 4). A
small amount of each sample was concurrently analyzed by
acrylamide gel electrophoresis to confirm that UV treatment was
successful in degrading the PC-oligo below detection limits (Figure
S4 in Supporting Information S1). Taken together, the results
indicate that light-induced degradation of incorporated PC-oligo
into 5-mers had no specific effect on the ability of PrP
Sc to seed
sPMCA reactions of normal brain homogenate.
Light- and dark-treated PrP
Sc containing either dT-oligo or PC-
oligo were injected intracerebrally into Golden Syrian hamsters for
bioassay. In addition, negative control samples consisting of either
the original Sc237 seed propagated for 15 rounds in PrP
C
substrate without nucleic acid (designated PrP
C) or a cocktail
containing the dT-oligo and PC-oligo (designated dT/PC-oligo
alone) were inoculated in parallel. The scrapie incubation time for
all 4 experimental groups was ,150 days, with all of the
inoculated animals developing similar clinical signs of ataxia,
trembling, and circling (Table 1). Animals injected with the PrP
C
and dT/PC-oligo control samples did not develop signs of clinical
scrapie during the time frame of the experiment (Table 1 and
figures 5A and 5B). Neuropathological analysis showed significant
vacuolization throughout the brains of animals in all 4 groups,
including the brainstem and hippocampus (Figure 5A and 5B),
and a blinded comparison of vacuolization scores from different
brain regions showed no difference between the experimental
groups (Figure 6). Biochemical analysis showed no differences in
the protease sensitivity, glycoform ratio, or electrophoretic
mobility of the PrP
Sc molecules produced in the brains of animals
from all 4 experimental groups (Figure S5 in Supporting
Information S1). There was also no apparent difference in the
conformational stability of PrP
Sc molecules in the brains of animals
injected with light-treated versus control inocula, as determined by
a urea denaturation assay (Figure S6 in Supporting Information
S1). Therefore, these results indicate that degradation of an
incorporated polyanion does not significantly alter the biological
infectivity or the strain-dependent properties of purified Sc237
prions.
Figure 4. Western blot showing the final samples from 3 round
sPMCA reactions. Samples containing dT-oligo or PC-oligo were
seeded with a dilution of PrP
Sc which was either subjected to light
treatment or not, as indicated. All samples were subjected to limited
proteolysis with proteinase K.
doi:10.1371/journal.ppat.1002001.g004
Table 1. Prion incubation times in hamsters inoculated
intracerebrally with sPMCA generated prions.
Inoculum n/n0 Incubation Time (Days ± S.E.M.)
dT-Oligo–light 8/8 15361
dT-Oligo+light 6/6 15360
PC-Oligo–light 7/7 15161
PC-Oligo+light 5/5 15360
PrP
C 0/4 .182
dT/PC-Oligo alone 0/4 .182
The PrP
C sample was generated by serially propagating the original Sc237 seed
for 15 rounds in PrP
C substrate alone (without polyanion) at a 1:10 ratio in each
round. The dT/PC-Oligo alone inoculum contains a mixture of both
oligonucleotides as described in Methods.
doi:10.1371/journal.ppat.1002001.t001
Figure 5. Representative histological fields of brainstem and
hippocampus. Hemotoxylin and Eosin staining from animals injected
with in vitro generated PrP
Sc containing dT-oligo or PC-oligo treated
with or without light. Top row: animals injected with prions treated in
dark. Middle row: animals injected with prions treated with light.
Bottom row: control animals. A. Brain stem. (Scale bar, 100 mm). B.
Hippocampus. (Scale bar, 200 mm).
doi:10.1371/journal.ppat.1002001.g005
Prion Polyanion Degradation
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The major finding of this work is that selective degradation of
an incorporated photocleavable polyanion cofactor does not alter
the catalytic activity, infectivity, or strain properties of in vitro
generated prions.
These results contrast with those of Jeong et al., who showed that
treatment of scrapie-infected brain homogenates with LiAlH4
caused degradation of endogenous RNA and increased prion
incubation time from ,100 to ,340 days [20]. There are several
possible reasons for the discrepancy between the two studies: (1)
Although both LiAlH4 and UV light treatment are capable of
reacting non-specifically with non-polyanionic molecules, under
the conditions used for each study, it is possible that LiAlH4
treatment is more non-specifically damaging than UV light. For
instance, it could reduce PrP
Sc molecules and/or directly damage
protein structure. (2) The work of Jeong et al. used scrapie brain
homogenate as the starting infectious material, whereas the
experiments reported here used purified prions formed from
native PrP
C substrate in vitro using sPMCA. Such purified prions
are composed only of PrP, stoichiometric amounts of an
endogenous lipid molecule containing 20 carbon fatty acids, and
a synthetic polyanion [5]. (3) Whereas LiAlH4 is capable of
hydrolyzing RNA molecules completely, UV light degrades the
PC-oligo used in our study to (dT)5 oligonucleotides. Although
such small nucleic acids do not support prion propagation in vitro,
our results cannot formally exclude the possibility that short
oligonucleotides, once incorporated, might be able to act as a
reinforcing backbone for PrP
Sc. (4) Although we did not detect any
intact PC-oligo after light treatment using a highly sensitive
intercalating agent, it is possible that a small, undetectable amount
of PC-oligo was protected from UV-irradiation by virtue of being
complexed with PrP
Sc molecules. This possibility is difficult to
address experimentally because it is technically difficult to recover
and detect such small amounts of DNA that cannot be amplified.
It is worth noting that UV light degrades PC-oligo quantitatively
within nuclease-resistant complexes with recombinant PrP.
Our results are compatible with the scenario in which prion
infectivity might be exclusively encoded by PrP
Sc structure in the
absence of non-proteinaceous cofactors, as proposed by the
‘‘protein only’’ hypothesis [23,24]. However, this hypothesis
cannot be confirmed in our experimental system because both
endogenous lipid and remnant (dT)5 oligonucleotide molecules
remain present in purified prions generated with PC-oligo
following light treatment. Nonetheless, we are able to conclude
that it is unnecessary for prions to contain polyanions .5 bases in
length to maintain infectivity, whereas polyanions $40 bases are
required for the process of prion formation in vitro. This conclusion
places a significant geometric constraint on the mechanism by
which polyanionic cofactors could be theoretically used to
maintain PrP
Sc architecture. Stoichiometric quantities of endog-
enous lipids containing 20-carbon fatty acids co-purify with the
PrP
C substrate used in these studies [5], and therefore these lipid
molecules could also become incorporated into the infectious
PrP
Sc product during PMCA reactions. Future studies will be
required to test whether endogenous lipid molecules or other non-
nucleic acid cofactors, such as those recently described in mouse
brain homogenates [25,26], might be required to maintain prion
infectivity and strain phenotypes.
Supporting Information
Supporting Information S1 Supporting Figures S1 through S6
Found at: doi:10.1371/journal.ppat.1002001.s001 (2.3MB DOC)
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